HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Self-reported treatment-associated symptoms among patients with urea cycle disorders participating in glycerol phenylbutyrate clinical trials.

AbstractBACKGROUND:
Health care outcomes have been increasingly assessed through health-related quality of life (HRQoL) measures. While the introduction of nitrogen-scavenging medications has improved survival in patients with urea cycle disorders (UCDs), they are often associated with side effects that may affect patient compliance and outcomes.
METHODS:
Symptoms commonly associated with nitrogen-scavenging medications were evaluated in 100 adult and pediatric participants using a non-validated UCD-specific questionnaire. Patients or their caregivers responded to a pre-defined list of symptoms known to be associated with the use of these medications. Responses were collected at baseline (while patients were receiving sodium phenylbutyrate [NaPBA]) and during treatment with glycerol phenylbutyrate (GPB).
RESULTS:
After 3 months of GPB dosing, there were significant reductions in the proportion of patients with treatment-associated symptoms (69% vs. 46%; p<0.0001), the number of symptoms per patient (2.5 vs. 1.1; p<0.0001), and frequency of the more commonly reported individual symptoms such as body odor, abdominal pain, nausea, burning sensation in mouth, vomiting, and heartburn (p<0.05). The reduction in symptoms was observed in both pediatric and adult patients. The presence or absence of symptoms or change in severity did not correlate with plasma ammonia levels or NaPBA dose.
CONCLUSIONS:
The reduction in symptoms following 3 months of open-label GPB dosing was similar in pediatric and adult patients and may be related to chemical structure and intrinsic characteristics of the product rather than its effect on ammonia control.
AuthorsSandesh C S Nagamani, George A Diaz, William Rhead, Susan A Berry, Cynthia Le Mons, Uta Lichter-Konecki, James Bartley, Annette Feigenbaum, Andreas Schulze, Nicola Longo, William Berquist, Renata Gallagher, Dennis Bartholomew, Cary O Harding, Mark S Korson, Shawn E McCandless, Wendy Smith, Jerry Vockley, David Kronn, Robert Zori, Stephen Cederbaum, J Lawrence Merritt 2nd, Derek Wong, Dion F Coakley, Bruce F Scharschmidt, Klara Dickinson, Miguel Marino, Brendan H Lee, Masoud Mokhtarani
JournalMolecular genetics and metabolism (Mol Genet Metab) 2015 Sep-Oct Vol. 116 Issue 1-2 Pg. 29-34 ISSN: 1096-7206 [Electronic] United States
PMID26296711 (Publication Type: Clinical Trial, Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Phenylbutyrates
  • Ammonia
  • 4-phenylbutyric acid
  • Glycerol
  • glycerol phenylbutyrate
Topics
  • Adolescent
  • Adult
  • Aged
  • Ammonia (blood)
  • Antineoplastic Agents (therapeutic use)
  • Child
  • Child, Preschool
  • Female
  • Glycerol (adverse effects, analogs & derivatives, chemistry, therapeutic use)
  • Humans
  • Infant
  • Male
  • Middle Aged
  • Phenylbutyrates (adverse effects, chemistry, therapeutic use)
  • Quality of Life
  • Self Report
  • Surveys and Questionnaires
  • Urea Cycle Disorders, Inborn (blood, drug therapy, psychology)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: